NCT05388916Completed
A Real-world Study to Assess Safety and Effectiveness of Secukinumab in Pediatric Plaque Psoriasis Patients in China
A Real-world, Prospective, Multicenter Study to Assess the Safety and Effectiveness of Secukinumab (Cosentyx®) in Patients Aged 6 to Less Than 18 Years With Moderate to Severe Chronic Plaque Psoriasis in China
Source: ClinicalTrials.gov · Last updated 29 Dec 2025
Brief summary (registry, in English)
This was a non-interventional, prospective, multi-center real world setting study, aiming to provide safety and effectiveness data in Chinese pediatric patients with moderate to severe plaque psoriasis treated with Cosentyx® for up to 52 weeks.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 42 (actual)
- First submitted
- 19 May 2022
- Start date
- 8 Sept 2022
- Primary completion date
- 27 Feb 2025
- Lead sponsor
- Novartis Pharmaceuticals
- Diseases
- Psoriasis
- NCT number
- NCT05388916
What you commit to
- Study type: Observational
- Participants enrolled: 42
- From 8 Sept 2022 to the primary completion date, 27 Feb 2025
- 7 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients previously treated with other biologics.
- Patients participating in other clinical trials or who previously participated in clinical trials within 30 days before Cosentyx® initiation or a period of 5 half-lives of the investigational drug, whichever is longer.
Other illness
- Patients in conditions which in the judgment of the clinical investigator renders the patient unsuitable for the study.
Other
- Patients meeting any of the following criteria are not eligible for inclusion in this study:
Who the study is looking for
- Patients meeting all of the following criteria are eligible for inclusion in this study:
- Written assent and informed consent must be obtained as per local regulations prior to any study procedures.
- Diagnosed with moderate to severe plaque psoriasis.
- Initiating treatment with Cosentyx® or having started Cosentyx® treatment within the last 4 weeks in routine clinical practice, and its prescription is independent of this study.
- Aged 6 to less than 18 years at the time they are prescribed Cosentyx®.
- Have valid PASI and IGA mod 2011 score at the time they are prescribed Cosentyx®.
Age in the registry: 6 years to 18 years · Sex: All · Does not accept healthy volunteers
Sites (7)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
| - Coordinator of this site? Confirm its status | Guangzhou | China | Unknown status |
| - Coordinator of this site? Confirm its status | Hangzhou | China | Unknown status |
| - Coordinator of this site? Confirm its status | Shenyang | China | Unknown status |
| - Coordinator of this site? Confirm its status | Shijiazhuang | China | Unknown status |
| - Coordinator of this site? Confirm its status | Xian | China | Unknown status |
| - Coordinator of this site? Confirm its status | Zhengzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.